Ependymoma, Recurrent Active Not Recruiting Phase 2 Trials for Tazemetostat (DB12887)

Also known as: Ependymoma Recurrent / Recurrent Ependymoma

IndicationStatusPhase
DBCOND0106575 (Ependymoma, Recurrent)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03213665Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)Treatment